[Secondary hyperlipoproteinemia: It is not always as it seems].
Waldmann-Roth E, Parhofer KG.
MMW Fortschr Med. 2025 Apr;167(6):56-59. doi: 10.1007/s15006-025-4776-z.
Experimental models of hyperlipoproteinemia and atherosclerosis.
Poledne R, Jurčíková-Novotná L.
Physiol Res. 2017 Apr 5;66(Suppl 1):S69-S75. doi: 10.33549/physiolres.933585.
Hyperlipoproteinemia(a): clinical significance and treatment options.
Berthold HK, Gouni-Berthold I.
Atheroscler Suppl. 2013 Jan;14(1):1-5. doi: 10.1016/j.atherosclerosissup.2012.10.037.
Molecular Therapeutics in Development to Treat Hyperlipoproteinemia.
Ahmad M, Hegele RA.
Mol Diagn Ther. 2025 May;29(3):291-305. doi: 10.1007/s40291-024-00768-0. Epub 2025 Jan 28.
Pregnancy-induced hyperlipoproteinemia: review of the literature.
Basaran A.
Reprod Sci. 2009 May;16(5):431-7. doi: 10.1177/1933719108330569. Epub 2009 Feb 20.
Lipemia Retinalis in a Baby with Hyperlipoproteinemia.
Maytal A, Ela-Dalman N.
Ophthalmology. 2022 Mar;129(3):321. doi: 10.1016/j.ophtha.2021.07.028.
Hyperlipoproteinemia in adults with renal disease.
Anderson CF.
Mayo Clin Proc. 1993 Apr;68(4):358-62. doi: 10.1016/s0025-6196(12)60131-1.
[Hyperlipoproteinemia in children].
Urbanová Z.
Vnitr Lek. 2016 Fall;62(11):882-886.
Primary and secondary prevention of cardiovascular disease in patients with hyperlipoproteinemia (a).
Grützmacher P, Öhm B, Szymczak S, Dorbath C, Brzoska M, Kleinert C.
Clin Res Cardiol Suppl. 2017 Mar;12(Suppl 1):22-26. doi: 10.1007/s11789-017-0090-3.
Diabetic hyperlipoproteinemia.
Schüller A, Alvarez Hernádez J.
Riv Eur Sci Med Farmacol. 1987 Sep;9(3):243-55.
